Johnson & Johnson to buy heart device maker Abiomed in $16.6bn deal
Johnson & Johnson has agreed to buy cardiovascular technology group Abiomed for $16.6bn, including debt, a sign that mega dealmaking remains robust in the US despite geopolitical and economic uncertainty globally.The US-based…